Adjuvant chemotherapy decisions in breast cancer are increasingly based on the
pathologist's assessment of tumor proliferation. The Swiss Working Group of Gyneco-and …

Ki67 expression has been a valuable prognostic variable in breast cancer, but has not seen
broad adoption due to lack of standardization between institutions. Automation could …

Breast cancer is the most common malignancy in women in the United States and is second
only to lung cancer as a cause of cancer death. The overall management of breast cancer …

Background Tumor microenvironment of metastasis (TMEM), consisting of direct contact
between a macrophage, an endothelial cell, and a tumor cell, has been associated with …

Aims To correlate Ki67 expression with outcome in colorectal cancer (CRC). Methods Ki67
labelling index (Ki67LI) was analysed by immunohistochemistry on a tissue microarray …

Clinical oncology is advancing toward a more personalized treatment orientation, making
the need to understand the biology of metastasis increasingly acute. Dissecting the complex …

Background The aim of this study was to investigate the prognostic value of the PAM50
intrinsic subtypes and risk of recurrence (ROR) score in patients with early breast cancer …

BACKGROUND: Positron emission tomography (PET) imaging using the radiotracer 18F-
Fluorothymidine (FLT) has been proposed as an imaging biomarker of tumour proliferation …

Obesity is the strongest risk factor for endometrial cancer (EC). To inform targeted screening
and prevention strategies, we assessed the impact of obesity and subsequent bariatric …

Pathological analysis of the nuclear proliferation biomarker Ki67 has multiple potential roles
in breast and other cancers. However, clinical utility of the immunohistochemical (IHC) assay …